The interim financial statements included herein are
unaudited but reflect, in management’s opinion, all adjustments, consisting only of normal recurring adjustments that are necessary
for a fair presentation of our financial position and the results of our operations for the interim periods presented. Because of the
nature of our business, the results of operations for the quarterly period and the three months ended March 31, 2022, are not necessarily
indicative of the results that may be expected for the full fiscal year.
Earth Life Sciences Inc. |
Balance Sheets |
As at |
(unaudited) |
|
|
Note |
|
March 31, 2022 |
|
|
December 31, 2021 |
|
ASSETS |
|
|
|
|
|
|
|
|
|
|
Current Assets |
|
|
|
|
|
|
|
|
|
|
Prepaid expenses |
|
|
|
$ |
600 |
|
|
$ |
600 |
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition of software technology |
|
|
|
|
4,426,000 |
|
|
|
4,426,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
|
|
$ |
4,426,600 |
|
|
$ |
4,426,600 |
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES |
|
|
|
|
|
|
|
|
|
|
Current Liabilities |
|
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities |
|
|
|
$ |
109,358 |
|
|
$ |
78,655 |
|
Notes payable |
|
|
|
|
49,919 |
|
|
|
49,018 |
|
Convertible debt |
|
|
|
|
249,325 |
|
|
|
245,135 |
|
|
|
|
|
|
408,602 |
|
|
|
372,808 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common shares, authorized 1,000,000,000 shares at par value $0.001, issued and outstanding as of March 31, 2022, and December 31, 2021 - 960,468,779. |
|
|
|
|
960,468 |
|
|
|
960,468 |
|
Additional paid in capital |
|
|
|
|
21,666,513 |
|
|
|
21,666,513 |
|
Accumulated comprehensive income |
|
|
|
|
131,859 |
|
|
|
131,859 |
|
Deficit |
|
|
|
|
(18,740,842 |
) |
|
|
(18,705,048 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,017,842 |
|
|
|
4,053,792 |
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders’ equity |
|
|
|
$ |
4,426,600 |
|
|
$ |
4,426,600 |
|
The Accompanying notes are integral part of these unaudited
financial statements.
Earth Life Sciences Inc. |
Statement of Operations
Unaudited |
| |
Three months ended March 31, 2022 | |
Three months ended March 31, 2021 |
Expenses | |
| | | |
| | |
Consulting and subcontractors | |
$ | 28,500 | | |
$ | 5,000 | |
Interest | |
| 5,091 | | |
| 4,996 | |
Office and general | |
| 2,203 | | |
| 3,058 | |
Stock-based compensation | |
| — | | |
| 1,519,544 | |
| |
| 35,794 | | |
| 1,532,598 | |
Net loss for the period | |
| (35,794 | ) | |
| (1,532,598 | ) |
Total comprehensive income (loss) | |
$ | (35,794 | ) | |
$ | (1,532,598 | ) |
Loss per share, basic and diluted | |
$ | — | | |
$ | — | |
| |
| | | |
| | |
Weighted average number of shares outstanding | |
| 960,468,779 | | |
| 960,468,779 | |
The Accompanying notes are integral part of these unaudited
financial statements.
Earth Life Sciences Inc. |
Statements of Cash Flows |
(unaudited) |
| |
Three months ended March 31, 2022 | |
Three months ended March 31, 2021 |
Cash Flows from Operating Activities | |
| | | |
| | |
| |
| | | |
| | |
Loss for the period | |
$ | (35,794 | ) | |
$ | (1,532,598 | ) |
Items not affecting cash: | |
| | | |
| | |
Accrued interest | |
| 4,291 | | |
| 4,996 | |
Stock-based compensation | |
| — | | |
| 1,519,544 | |
| |
| (30,220 | ) | |
| (8,058 | ) |
Changes in non-cash working capital: | |
| | | |
| | |
Prepaid expenses | |
| — | | |
| 4,000 | |
Accounts payable and accrued liabilities | |
| 30,703 | | |
| (8,812 | ) |
| |
| | | |
| | |
Net cash provided by (used in) operating activities | |
| (800 | ) | |
| (12,870 | ) |
| |
| | | |
| | |
Cash Flows from Financing Activities | |
| | | |
| | |
Advances received from a shareholder | |
| 800 | | |
| 12,870 | |
| |
| | | |
| | |
Net cash provided by financing activities | |
| 800 | | |
| 12,870 | |
| |
| | | |
| | |
Cash Flows from Investing Activities | |
| | | |
| | |
| |
| | | |
| | |
Net cash used in investing activities | |
| — | | |
| — | |
| |
| | | |
| | |
Change in cash and cash equivalents | |
| — | | |
| — | |
Cash and cash equivalents at beginning of period | |
| — | | |
| — | |
| |
| | | |
| | |
Cash and cash equivalents at end of period | |
$ | — | | |
$ | — | |
| |
| | | |
| | |
Interest paid | |
$ | — | | |
$ | — | |
Income taxes paid | |
$ | — | | |
$ | — | |
Shares issued in for debt | |
$ | — | | |
$ | 1,519,544 | |
| |
| | | |
| | |
The Accompanying notes are integral part of these unaudited
financial statements.
Earth Life Sciences Inc. |
Statements of Changes in Shareholders’ Equity |
(unaudited) |
| |
Share Capital | |
| |
| |
| |
|
| |
Shares | |
Amount | |
Additional paid-in capital | |
Deficit | |
Cumulative other comprehensive income | |
Total |
Balance, January 1, 2021 | |
| 464,817,339 | | |
$ | 464,817 | | |
$ | 16,321,969 | | |
$ | (17,120,553 | ) | |
$ | 131,859 | | |
$ | (201,908 | ) |
Shares issued for debt | |
| 50,651,440 | | |
| 50,651 | | |
| 1,519,544 | | |
| — | | |
| — | | |
| 1,570,195 | |
Loss for the period | |
| — | | |
| — | | |
| — | | |
| (1,532,598 | ) | |
| — | | |
| (1,532,598 | ) |
Balance, March 31, 2021 | |
| 515,468,779 | | |
$ | 515,468 | | |
$ | 17,841,513 | | |
$ | (18,653,151 | ) | |
$ | 131,859 | | |
| (164,311 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, January 1, 2022 | |
| 960,468,779 | | |
| 960,468 | | |
| 21,666,513 | | |
| (18,705,048 | ) | |
| 131,859 | | |
| 4,053,792 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Loss for the period | |
| — | | |
| — | | |
| — | | |
| (35,794 | ) | |
| — | | |
| (35,794 | ) |
Balance, March 31, 2022 | |
| 960,468,779 | | |
$ | 960,468 | | |
$ | 21,666,513 | | |
$ | (18,740,842 | ) | |
$ | 131,859 | | |
$ | 4,017,998 | |
The Accompanying notes are integral part of these unaudited
financial statements.
EARTH LIFE SCIENCES INC. |
(A Development Stage Company) |
|
NOTES TO THE FINANCIAL STATEMENTS |
March 31, 2022 |
NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS
Earth Life Sciences Inc. (the “Company”)
was incorporated in the state of Nevada on November 2, 2001. Originally the corporate name was Altus Explorations, Inc. On June 2, 2014,
the Company changed its name to Earth Life Sciences Inc.
On October 1, 2010, the Company entered into an Agreement
(the “Agreement”) with UWD Unitas World Development Inc. (“UWD”), a privately held Canadian incorporated company.
Pursuant to the Agreement, the Company issued 80,000,000 shares of common stock for the acquisition 100% of the issued shares of Canadian
Tactical Training Academy Inc (“CTTA”). The Company operations consisted of the training of law enforcement, security, investigation
and protection for officers and individuals. During the year ended December 31, 2015, the Company discontinued the operations of the subsidiary,
CTTA, and returned the shares of CTTA.
On June 12, 2015, the Company, through an option agreement,
issued 225,000,000 shares to Mr. Song Bo, to earn the mineral rights for the White Channel mineral claims located in British Columbia.
The Company embarked on mineral exploration program. During the year ended December 31, 2017, the Company terminated the exploration and
development of the White Channel property based on unfavorable economics of the mineral resources. The Company returned 225,000,000 shares
held in trust to the Company treasury in 2020.
In 2020 the Company entered into the transportation
software market, and in 2021 the Company entered into the digital healthcare services through the mode of online ordering and offline
service (“O2O”). See (Note 3).
These financial statements have been prepared on
a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal
course of business. The Company is unlikely to pay dividends or generate significant earnings in the immediate or foreseeable
future. The continuation of the Company as a going concern and the ability of the Company to emerge from the Development stage are
dependent upon management’s successful efforts to raise additional equity financing to continue operations and generate
sustainable significant revenues.
These financial statements do not include any adjustments
to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the
Company be unable to continue as a going concern. The Company will require significant additional financial resources and will be dependent
on future financings to fund its ongoing operations as well as other working capital requirements. There is no guarantee that management
will be able to raise adequate equity financings or generate profits from operations. These factors raise substantial doubt regarding
the Company’s ability to continue as a going concern.
Management of the Company has undertaken steps as
part of a plan with the goal of sustaining Company operations for the next twelve months and beyond. These steps include: (a) continuing
efforts to raise additional capital and/or other forms of financing; and (b) controlling overhead and expenses. Management is aware that
material uncertainties exist, related to current economic conditions, which could cast a doubt about the Company’s ability to continue
to finance its activities. It is to be expected that the Company may incur further losses in the Development of its business and there
can be no assurance that any of these efforts will be successful.
NOTE 2 - SUMMARY OF ACCOUNTING POLICIES
Basis of Presentation
The financial statements of the Company have been
prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and are expressed
in U.S. dollars. The Company’s fiscal year-end is December 31.
Use of Estimates
The preparation of financial statements in conformity
with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during
the reporting periods. Actual results could materially differ from those estimates and assumptions. Significant areas requiring the use
of management estimates relate to the determination of impairment of long-lived assets, expected tax rates for future income tax recoveries
and determining the fair values of financial instruments.
Equipment
Equipment is recorded at cost. Additions are capitalized
and maintenance and repairs are charged to expense as incurred. Gains and losses on dispositions of equipment are reflected in operations.
Depreciation is provided using the straight-line method over the estimated useful lives of the assets.
Impairment of Assets
The Company reviews the carrying value of its long-lived
assets annually or whenever events or changes in circumstances indicate that the historical carrying value of an asset may no longer be
appropriate. The Company assesses recoverability of the carrying value cost of the asset by estimating the future net cash flows expected
to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset,
an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value.
Other Comprehensive Income
The Company reports and displays comprehensive income
and its components in the financial statements. During the periods ended March 31, 2022, and 2021, the Company recorded unrealized foreign
exchange gains of $nil and $nil respectfully.
Income Taxes
The Company uses the asset and liability method of
accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences
attributable to temporary differences between the financial statements carrying amounts of assets and liabilities and their respective
tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled.
The Company recognizes the financial statement benefit
of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an
audit. For tax positions meeting this standard, the amount recognized in the financial statements is the largest benefit that has a greater
than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.
Basic and Diluted Loss per Share
Basic loss per share is computed using the weighted
average number of common shares outstanding during the year. Diluted earnings per share reflect the potential dilution that could occur
if potentially dilutive securities were exercised or converted to common stock. The dilutive effect of options and warrants and their
equivalent is computed by application of the treasury stock method and the effect of convertible securities by the “if converted”
method. For the years presented, diluted loss per share is equal to basic loss per share as the effect of the computations are anti-dilutive.
Financial Instruments
The Company’s balance sheet includes financial
instruments, specifically accounts payable, accrued expenses, and payables to related parties. The carrying amounts of current assets
and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments
and their expected realization.
ASC 820, Fair Value Measurements and Disclosures,
defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on
market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant
assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists
of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
Level 1 - Unadjusted quoted prices in active
markets that are accessible at the measurement date for identical, unrestricted assets or liabilities
Level 2 - Inputs other than quoted prices
included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar
assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active;
inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally
from or corroborated by observable market data by correlation or other means.
Level 3 - Inputs that are both significant
to the fair value measurement and unobservable.
Fair value estimates discussed herein are based upon
certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet
financial instruments approximated their fair values due to the short-term nature of these instruments.
Revenue Recognition
The Company follows ASC 605, Revenue Recognition -The
Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned
when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the
services have been rendered to the customer, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured.
The Company provides services to companies on a time and materials basis and recognizes revenues upon billing of time and materials at
which all services have been completed and there is no warranty or returns on services.
Deferred Income Taxes and Valuation Analysis
The Company accounts for income taxes under ASC 740
Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future
tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and
their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income
in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities
of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred
tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets
or liabilities were recognized as of March 31, 2022, or December 31, 2021.
Net Income (loss) per Common Share
Net income (loss) per share is calculated in accordance
with ASC 260, “Earnings Per Share.” The weighted-average number of common shares outstanding during each period is used to
compute basic earning or loss per share. Diluted earnings or loss per share is computed using the weighted average number of shares and
diluted potential common shares outstanding. Dilutive potential common shares are additional common shares assumed to be exercised.
Basic net income (loss) per common share is based
on the weighted average number of shares of common stock outstanding at March 31, 2022, and 2021.
Share Based Compensation
ASC 718, Compensation – Stock Compensation,
prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions
include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership
plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as
compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an
employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).
The Company accounts for stock-based compensation
issued to non-employees and consultants in accordance with the provisions of ASC 505-50, Equity – Based Payments to Non-Employees.
Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable:
(a) the goods or services received; or (b) the equity instruments issued.
Share-based expense for the periods ended March 31,
2022, and 2021 totaled $nil and $1,519,544 respectively.
NOTE 3 – SOFTWARE TECHNOLOGIES
The Company entered into an agreement with the
Software Group in January of 2020. The Company issued 32,000,000 restricted common shares to the four members of the Software Group
as general consideration at a fair value of $176,000. The Company also issued 325 million common shares to an escrow agent. Pursuant
to the terms of the agreement the escrow agent will transfer 125 million shares to the Software Group upon the Company receiving a
working version of the software and necessary support documentation, after testing, acceptance, and license transfer of the
software. Further transfer of 100 million shares held by the escrow agent will be based on gross sales of $1 million being reached
in a consecutive twelve-month period within 3 years, and a further 100 million shares after gross sales of $5 million being reached
in a consecutive twelve-month period within 5 years. All shares issued were restricted.
In October 2021 the Company entered into an acquisition agreement
with VIVA Health HK Limited, a “one-stop smart branded” healthcare service, to be implemented in the United States. VIVA utilizes
artificial intelligence and big data, through their platform to provide health care services. The customized platform is proposed to address
American needs to provide services through the mode of online ordering and offline service (“O2O”), the services being a one-stop
smart life service branded platform, oriented to the health care industry and designed to meet the needs of seniors and particularly of
Asian descent.
Under the terms of the agreement,
the Company issued 425 million common shares to an escrow agent at a fair value of $4,250,000 and upon receiving a satisfactory minimum
viable product version and a Beta version completed and demonstrated with
necessary support documentation, the Escrow Agent will transfer the shares to Viva. A further issuance of 750 million shares will be issued upon
the O2O website going fully live and operational. All shares being issued are restricted.
NOTE 4 – CONVERTIBLE NOTE PAYABLE
As of March 31, 2022, the Company had convertible
notes payable totaling $249,325 (December 31, 2021 - $245,135). Convertible notes were issued on July 1, 2020, pursuant to the conversion
of Notes Payable of $264,883 as of June 30, 2020 (Amounts payable December 31, 2019, of $248,103). Previously convertible notes payable
consisted of the conversion of a Notes Payable in 2011 and had no interest rate and no fixed terms of repayment. The recent convertible
notes payable have an interest rate of 8% commencing on January 1, 2021. The notes are convertible into common shares at $0.001 per share.
Currently, the notes could be converted to 249,325,000 shares.
NOTE 5 – COMMON STOCK
As of March 31, 2022, the Company had 1,000,000,000
shares of $0.001 par value common shares authorized. On October 8, 2020, the authorized share capital was increased from 500,000,000 shares
to 1,000,000,000 common shares.
NOTE 6 – INCOME TAXES
The Company is subject to United States federal and
state income taxes at an approximate rate of 27%. The amount taken into income as deferred income tax assets must reflect that portion
of the income tax loss carry forwards that is more likely-than-not to be realized from future operations. The Company has chosen to provide
a full valuation allowance against all available income tax loss carry forwards, regardless of their time of expiry.
No provision for income taxes has been provided in
these financial statements due to the net loss for the periods ended March 31, 2022, and 2021. The potential tax benefit of these losses
may be limited due to certain change in ownership provisions under Section 382 of the Internal Revenue Code and similar state provisions.
NOTE 7 – NOTES PAYABLE
As of March 31, 2022, the Company had notes payable
of $49,919 (December 31, 2021 - $49,018). The notes are repayable to arms-length lenders for advances received by the Company starting
in 2015. On June 30, 2020, the Company agreed to pay interest at the rate of 8% per annum starting on January 1, 2021. The notes payable
are payable on demand. On July 1, 2020, Notes Payable of $264,883 were changed to convertible notes payable. See Note 4.
NOTE 8 – SUBSEQUENT EVENTS
On April 19, 2022, the Company issued 39,422,820 shares
pursuant to the conversion of convertible notes payable at the rate of $0.001 per share. See note 4, Convertible Note Payable.